Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of once-daily Treprostinil Palmitil Inhalation Powder (TPIP) in participants with pulmonary arterial hyperten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Treprostinil Palmitil Inhalation Powder (TPIP) (treprostinil palmitil inhalation powder)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: NOT_YET_RECRUITING